Genotype-phenotype correlations in L1 syndrome: a guide for genetic counselling and mutation analysis


Published in:
Journal of Medical Genetics

DOI:
10.1136/jmg.2009.071688

Link to publication

Citation for published version (APA):
Genotype—phenotype correlations in L1 syndrome: a guide for genetic counselling and mutation analysis


ABSTRACT

Objectives To develop a comprehensive mutation analysis system with a high rate of detection, to develop a tool to predict the chance of detecting a mutation in the L1CAM gene, and to look for genotype—phenotype correlations in the X-linked recessive disorder, L1 syndrome.

Methods DNA from 367 referred patients was analysed for mutations in the coding sequences of the gene. A subgroup of 100 patients was also investigated for mutations in regulatory sequences and for large duplications. Clinical data for 106 patients were collected and used for statistical analysis.

Results 68 different mutations were detected in 73 patients. In patients with three or more clinical characteristics of L1 syndrome, the mutation detection rate was 66% compared with 16% in patients with fewer characteristics. The detection rate was 51% in families with more than one affected relative, and 18% in families with one affected male. A combination of these two factors resulted in an 85% detection rate (OR 10.4, 95% CI 3.6 to 30.1). The type of mutation affects the severity of L1 syndrome. Children with a truncating mutation were more likely to die before the age of 3 than those with a missense mutation (52% vs 8%, p=0.02).

Conclusions We developed a comprehensive mutation detection system with a detection rate of almost 20% in unselected patients and up to 85% in a selected group. Using the patients’ clinical characteristics and family history, clinicians can accurately predict the chance of finding a mutation. A genotype-phenotype correlation was confirmed. The occurrence of (maternal) germline mosaicism was proven.

INTRODUCTION

L1 syndrome is an X-linked recessive disease caused by mutations in the L1CAM gene. The phenotypic spectrum includes X-linked hydrocephalus, also referred to as hydrocephalus due to stenosis of the aqueduct of Sylvius (HAS; MIM 307000), MASA syndrome (mental retardation, aphasia, shuffling gait and adducted thumbs; MIM 503550), X-linked complicated hereditary spastic paraplegia type 1 (SPG1; MIM 503550) and X-linked complicated corpus callosum agenesis (X-linked ACC; MIM 304100).1 2 The seriousness of the disease may vary from severe hydrocephalus and prenatal death (HAS syndrome subtype) to a mild phenotype (MASA syndrome subtype). These variations may even occur in the same family.3 4

The L1CAM gene, coding for the neural cell adhesion molecule (L1), is located on the X chromosome. The gene consists of 29 exons, the first being non-coding. The protein of 1257 amino acids is a transmembrane glycoprotein belonging to the immunoglobulin (Ig) superfamily cell adhesion molecules and contains, besides a signal peptide, 15 distinct domains—that is, six Ig and five fibronectin III-like domains at the extracellular surface, one single-pass transmembrane domain and one short cytoplasmic domain.

To our knowledge, 169 different L1CAM mutations have been published; 130 of these were catalogued in 2001 and an additional 39 were published more recently.6–22 Most L1CAM mutations are unique to each family—that is, they appear to be private mutations. Only a few families harbour the same recurrent mutation.

L1CAM mutation analysis is offered to all patients suspected of having L1 syndrome. Once a mutation has been established, prenatal testing can be performed in subsequent pregnancies, and carriership testing can be carried out to determine the potential presence of an L1CAM mutation in female relatives. Optimisation of the previously reported L1CAM mutation detection system23 has allowed us to investigate 367 L1 syndrome referrals. The analysis resulted in a mutation frequency of almost 20%. Although this is a good score, the question remains whether this relatively low frequency is due to the inclusion of large numbers of patients who do not have L1 syndrome or we have missed mutations and should extend our mutation screening procedure. To investigate this, we screened additional regulatory sequences of the L1CAM gene for mutations and looked for duplications and deletions. Furthermore, we evaluated the clinical data of a large set of patients to see if this could help in predicting the mutation status. Finally, we analysed genotype—phenotype correlations with the severity of the disease.

PATIENTS, MATERIALS AND METHODS

Patients All patients (n=367), from various parts of the world, analysed in our laboratory for diagnostic L1CAM testing were included. If no DNA from the index patient was available (n=47), the DNA of the mother (n=38) was analysed or that of a close family member, a sister (n=6) or aunt (n=5). Of these patients, 78% were referred by clinical geneticists, 12% by (paediatric) neurologists and 10% by paediatricians.
To allow investigation of the mutation detection rate for specific subsets of patients, all referral clinicians were requested to complete a questionnaire.

**Mutation analysis using denaturing gradient gel electrophoresis (DGGE)**

Mutation analysis of the *L1CAM* gene was performed, using DGGE analysis followed by direct sequencing of fragments showing an aberrant DGGE pattern, essentially as previously described. The amplicons 1, 7, 15, 16β, 18, 21 and 25 are routinely analysed by direct sequencing using the same primers as developed for DGGE, but with an M13 tail instead of the GC clamp.

**Sequence analysis of regulatory regions**

Analysis of *L1CAM* regulatory regions—that is, about 1000 bp of the promoter region (including the non-coding first exon of the gene, called exon A), the neural restrictive silencer element (NRSE) and the homeodomain and paired domain binding site (HPD) (figure 1)—was performed by direct sequencing of these regions. The NRSE, within intron 1 of the gene, restricts expression of L1 to the nervous system. The HPD is a positive regulatory element, which induces *L1CAM* gene expression.

Four primers sets were designed for the promoter region (PromA−PromD), one for the HPD region and one for the NRSE region (table 1). PCR was performed in a total reaction volume of 50 μl containing 5 μl 10×PCR buffer (Amersham Biosciences, Roosendaal, The Netherlands), 0.17 μl *Taq* polymerase (5000 U/ml, Amersham Biosciences), 20 pmol each primer (Eurogentec, Serian, Belgium), 10 pmol dNTPs (Amersham Pharmacia Biotech, Piscataway, New York) and 100 ng DNA. In addition, 5 μl dimethyl sulphoxide was added for two PCRs (PromA and PromB). For fragments PromC and PromD, the PCRx Enhancer System (Invitrogen Life Technologies, Breda, the Netherlands), 0.17 μl *Taq* polymerase (5000 U/ml, Amersham Biosciences), 20 pmol each primer (Eurogentec, Serian, Belgium), 10 pmol dNTPs (Amersham Pharmacia Biotech, Piscataway, New York) and 100 ng DNA. In addition, 5 μl dimethyl sulphoxide was added for two PCRs (PromA and PromB). For fragments PromC and PromD, the PCRx Enhancer System (Invitrogen Life Technologies, Breda, the Netherlands) was used with a final PCRx Enhancer Solution Concentration of 5×. A standard cycling protocol of 35 cycles was used with different annealing temperatures for each fragment (table 1). The PCR products were analysed on a 2% agarose gel; the remainder of the reaction volume was analysed by direct sequencing using the same primers as developed for DGGE, but with an M13 tail instead of the GC clamp.

Four primers sets were designed for the promoter region (PromA−PromD), one for the HPD region and one for the NRSE region (table 1). PCR was performed in a total reaction volume of 50 μl containing 5 μl 10×PCR buffer (Amersham Biosciences, Roosendaal, The Netherlands), 0.17 μl *Taq* polymerase (5000 U/ml, Amersham Biosciences), 20 pmol each primer (Eurogentec, Serian, Belgium), 10 pmol dNTPs (Amersham Pharmacia Biotech, Piscataway, New York) and 100 ng DNA. In addition, 5 μl dimethyl sulphoxide was added for two PCRs (PromA and PromB). For fragments PromC and PromD, the PCRx Enhancer System (Invitrogen Life Technologies, Breda, the Netherlands) was used with a final PCRx Enhancer Solution Concentration of 5×. A standard cycling protocol of 35 cycles was used with different annealing temperatures for each fragment (table 1). The PCR products were analysed on a 2% agarose gel; the remainder of the reaction volume was analysed by direct sequencing using the same primers as developed for DGGE, but with an M13 tail instead of the GC clamp.

Four primers sets were designed for the promoter region (PromA−PromD), one for the HPD region and one for the NRSE region (table 1). PCR was performed in a total reaction volume of 50 μl containing 5 μl 10×PCR buffer (Amersham Biosciences, Roosendaal, The Netherlands), 0.17 μl *Taq* polymerase (5000 U/ml, Amersham Biosciences), 20 pmol each primer (Eurogentec, Serian, Belgium), 10 pmol dNTPs (Amersham Pharmacia Biotech, Piscataway, New York) and 100 ng DNA. In addition, 5 μl dimethyl sulphoxide was added for two PCRs (PromA and PromB). For fragments PromC and PromD, the PCRx Enhancer System (Invitrogen Life Technologies, Breda, the Netherlands) was used with a final PCRx Enhancer Solution Concentration of 5×. A standard cycling protocol of 35 cycles was used with different annealing temperatures for each fragment (table 1). The PCR products were analysed on a 2% agarose gel; the remainder of the reaction volume was analysed by direct sequencing using the same primers as developed for DGGE, but with an M13 tail instead of the GC clamp.

**Table 1** Primer set regulatory regions

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence (5′→3′)</th>
<th>Length (bp)</th>
<th>Product size (bp)</th>
<th>AT (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PromA_F</td>
<td>GCCTGTTGAGGTCATGCCCCTTG</td>
<td>22</td>
<td>357</td>
<td>53</td>
</tr>
<tr>
<td>PromA_R</td>
<td>GGGGGCTCGGGTCCGTGTT</td>
<td>20</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>PromB_F</td>
<td>CCAACCGCTGAGGGAGGAAG</td>
<td>20</td>
<td>291</td>
<td>61.2</td>
</tr>
<tr>
<td>PromB_R</td>
<td>CAAGGCGGCCCTCTGAAAAA</td>
<td>20</td>
<td>291</td>
<td>61.2</td>
</tr>
<tr>
<td>PromC_F</td>
<td>AGGGGAGGGGAGAGGGGAGCACT</td>
<td>21</td>
<td>345</td>
<td>49.4</td>
</tr>
<tr>
<td>PromC_R</td>
<td>GGAGGGGAGGGGAGGGGAGGAAGATGAGAT</td>
<td>23</td>
<td>49.4</td>
<td></td>
</tr>
<tr>
<td>PromD_F</td>
<td>TGGCCAGGGCGGACTAGGTT</td>
<td>19</td>
<td>318</td>
<td>57</td>
</tr>
<tr>
<td>PromD_R</td>
<td>GGCGGCAGCGTGGTGTC</td>
<td>19</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>HPD_F</td>
<td>GGGCCCTCTCCACATCTCTCT</td>
<td>22</td>
<td>237</td>
<td>53</td>
</tr>
<tr>
<td>HPD_R</td>
<td>CTGGGGAGTGAACCTGTTGAT</td>
<td>22</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>NRSE_F</td>
<td>GCGGCTACCTCCGCGCTAT</td>
<td>20</td>
<td>331</td>
<td>50.9</td>
</tr>
<tr>
<td>NRSE_R</td>
<td>GGTGACGGAGGGAGAGTCG</td>
<td>20</td>
<td>50.9</td>
<td></td>
</tr>
</tbody>
</table>

All primers are designed with an M13 tail: (f) CGACGTTGTAAAACGACGGCCAGT and (r) CAGGAACAGATGAC.

AT, annealing temperature; HPD, homeodomain and paired domain binding site; NRSE, neural restrictive silencer element; Prom, Promoter.

cDNA analysis of a potential RNA splicing mutation

Total RNA was extracted from peripheral blood, using the RNABee procedure (Cinna Biotech, Friendswood, Texas, USA), and cDNA was obtained using the Ready-To-Go You-Prime First-Strand Beads for reverse transcription PCR with random hexamer primers pd(N)6 (Amersham Biosciences). Primers amplifying a product from exons 5 to 8 (f) CCAAATGCGCCAAAGGAGACAG and (r) ACTGCCCAGTGAGTTCTCG were used to characterise the cDNA sequence around the c.645C→T mutation in exon 6. The primers (f) CCAAATGCGCCAAAGGAGACAG and (r) TGATGGTGGGCGTGGGAAAG were used to verify the results obtained. The PCR products were loaded on to a 2% agarose gel, purified with ExoSAP-IT (Amersham Pharmacia Biotech) and subjected to direct sequencing using the primers described to confirm the presence of an aberrant transcript.

**Statistical analysis**

A study was carried out to determine whether, and in what way, the mutation detection rate was influenced by (α) the number of age-independent clinical characteristics (table 2), (β) the number of affected relatives and (γ) a combination of these factors.

An analysis was also performed to detect any possible genotype—phenotype correlation, notably between the severity of the disease and truncating or missense mutations. The disease was defined as severe if a child died before the age of 5.

For statistical analysis, the χ² test was carried out, except in cases of small numbers when the Fisher exact test was used. A logistic regression analysis was performed to calculate the odds ratio (OR).

The likely disease-causing mutations in these analyses are considered to be disease-causing.

**RESULTS**

**Mutation analysis using DGGE**

In total, 367 subjects—that is, 320 index patients and 47 relatives, in most cases the mother—were analysed for the presence of a mutation in the *L1CAM* gene. With this technique, a mutation was detected in 72 of the 367 subjects (online supplementary tables A and B). Sixty-seven different mutations were found: three mutations were detected in two families and one mutation

---

**Figure 1** 5′ site of the *L1CAM* gene with regulatory regions: promoter, homeodomain and paired domain binding site (HPD) and neural restrictive silencer element (NRSE). E1, exon 1; I1, intron 1. Exon A is 125 bp. 800 bp of the promoter region were analysed.
in three different families. Fifty-two mutations have not been published before. Five mutations have previously been reported in cooperation with us,9–10 18 19 26 and 10 mutations were also found by others22 27–34 (online supplementary table A). The disease-causing relevance of seven of the 67 mutations remained unclear (online supplementary table C). In addition to the 67 mutations, we also detected six variants that were probably not disease-causing (online supplementary table C). None of the variants in supplementary tables B and C match known single-nucleotide polymorphisms.

**Sequence analysis of the regulatory regions and MLPA analysis**

We extended our sequence analysis to the *L1CAM* promoter and the HPD and NRSE regions and performed an MLPA analysis to determine whether additional mutations were present in the regulatory sequences of the gene, or whether deletions or insertions could partly explain why the remaining 80% of patients did not have a detectable coding sequence mutation.

No mutation was detected in the promoter region, the non-coding sequence of the first exon, the HPD region or the NRSE site in 100 of the 295 subjects (randomly chosen) of our cohort not harbouring a mutation in the *L1CAM* gene. The regulatory sequences of the other 195 subjects have not been analysed.

MLPA analysis identified one subject with a duplication from exons 2–10. So, in total, a mutation was detected in 75 of the 367 subjects.

**RNA splicing mutation and germline mosaicism**

Reverse transcription PCR was carried out to determine a possible splice effect of the silent mutation c.645C→T. Figure 2 clearly shows that this mutation influences RNA splicing. Sequence data confirm that a new splice donor site is introduced in exon 6, causing a deletion of 51 bp at the 5′ site of the exon (figure 2).

In this case, a maternal germline mosaicism was also demonstrated; the mother did not carry the mutation, but a second male fetus did.

**Patients**

The questionnaire, covering the family anamnesis and the seven most important clinical parameters of L1 syndrome, was filled out for 135 of the 367 patients. Twenty-nine of these 135 patients were referred in order to exclude the disease. Statistical evaluation was therefore carried out on 106 patients, 31 of whom carried a mutation. The most important clinical data have been summarised in table 2. Known data for the remaining 252 patients have also been included in this table. It is clear that this group is less well characterised. Supplementary table A contains clinical data for patients harbouring an *L1CAM* mutation. As many patients die before birth or at a very young age, a distinction is made in characteristics that can be observed at birth or post mortem and those that can be observed only in later stages of life (table 2).

We also looked at the co-occurrence of a hydrocephalus (ventriculomegaly) and a macrocephaly (head circumference of >2SD). In the selected group, out of 91 patients with hydrocephalus, 36 also had a macrocephaly, 25 of which needed shunting.

In the event of a positive family history, there is always compatibility with X-linked recessive inheritance. However, in a few families comprising only a limited number of affected family members, autosomal recessive inheritance cannot be excluded.

**Statistical analysis**

The clinical data from 106 patients, obtained via the questionnaire, were used for statistical analysis as summarised in table 3. It can be seen that patients with three or more age-independent clinical L1 syndrome characteristics had a significantly higher percentage of mutations (66%) than patients with fewer than three characteristics (16%). This is also true for families with more than one affected family member: 51% vs 18% for families with only one affected family member. A combination of these two characteristics—that is, patients with a positive family history for L1 syndrome and having three or more clinical characteristics—resulted in a detection rate of 85%.

The OR of finding a mutation in patients with three or more clinical characteristics was 10.1 (95% CI 3.8 to 27.1). This

**Table 2 Characteristics of patients (n=338)**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Selected group (n=106)</th>
<th>Remnant group (n=232)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;1 affected relatives</td>
<td>35</td>
<td>60</td>
</tr>
<tr>
<td>Died at young age</td>
<td>29</td>
<td>63</td>
</tr>
<tr>
<td>Age-independent characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocephalus</td>
<td>91</td>
<td>133</td>
</tr>
<tr>
<td>Aque duct stenosis</td>
<td>46</td>
<td>15</td>
</tr>
<tr>
<td>Adducted thumbs</td>
<td>46</td>
<td>51</td>
</tr>
<tr>
<td>ACC/DCC</td>
<td>24</td>
<td>27</td>
</tr>
<tr>
<td>Age-dependent characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental retardation</td>
<td>56</td>
<td>46</td>
</tr>
<tr>
<td>Aphasia</td>
<td>37</td>
<td>10</td>
</tr>
<tr>
<td>Spastic paraplegia</td>
<td>36</td>
<td>49</td>
</tr>
<tr>
<td>No clinical data available</td>
<td>0</td>
<td>53</td>
</tr>
</tbody>
</table>

Characteristics of the total group of 367 patients minus the 29 patients tested for L1 syndrome exclusion.

ACC/DCC, agenesis/dysgenesis of the corpus callosum.

![Figure 2](A) cDNA analysis of patient 329. Agarose gel electrophoresis of cDNA exon 6 of the patient (P) and a control sample (Contr). Wild-type exon 6 is 418 bp long. G, genomic; Bl, blanco; M, marker. (B) Sequence analysis of cDNA exon 6 of patient 329. WT, wild-type; MT, mutant.
increased slightly to 10.4 (95% CI 3.6 to 30.1) when these patients also had two or more affected family members.

Applying the same calculations to the whole group of 338 patients (367 minus the 29 who were only been analysed to exclude the presence of L1 syndrome), some lacking relevant clinical information (table 2), the mutation detection rate was 18% in patients with fewer than three characteristics. In patients with three or more characteristics but no affected relatives, this rate increased to 58%, with an OR of 6.1 (95% CI 3.0 to 12.7). In the group of patients with three or more clinical characteristics and a positive family history, the detection rate increased to 79%, with an OR of 8.1 (95% CI 3.5 to 18.6) as compared with 85% in the selected group. These results are logical, as the second group was less well defined (unselected) and therefore showed a lower detection rate, but larger and therefore showed a smaller CI.

Interrelationships, as mentioned above, can be seen when the data from the whole group are used (figure 3). The chance of having a mutation increased when patients had more clinical characteristics, and even more when at least two family members were affected.

We also determined the positive predictive value of the individual clinical characteristics in relation to the presence of a mutation (table 4), showing the most predictive to be adducted thumbs (50%) and the least predictive to be mental retardation (32%).

Genotype—phenotype correlation

A statistical analysis was performed on 35 patients who were carrying a mutation to detect any possible genotype—phenotype correlation. Children harbouring a truncating mutation were more likely to die before the age of 3 (52%) than children with a missense mutation (8%). This indicates a relationship between the seriousness of the disease and the type of mutation. These results are significant (Fisher exact \( p = 0.02 \)) (table 5).

No significant difference was detected in the occurrence of one of the other clinical characteristics (including macrocephaly) comparing patients carrying a missense mutation with patients carrying a truncating mutation (online supplementary table D).

DISCUSSION

Mutation analysis was carried out on 367 referred cases (that is 320 index patients and 47 relatives). Seventy-two patients were shown to harbour 67 different mutations. One additional mutation was found with the MLPA test, making a total of 73 patients with a disease-causing mutation. The mutations comprise 23 missense mutations, three in-frame deletions/duplications, 18 splice site mutations, 14 nonsense mutations, eight frame-shift mutations, one duplication of exons 2–10, and one deletion of the entire gene. This implies that about 60% of all mutations are truncating and therefore considered to be disease-causing. This is less straightforward for the 23 missense mutations. However, the identified missense mutations are mostly considered to be disease-causing, as they often occur in the so-called key residues\(^{35}\) that are important for the structure of the Ig domains and the fibronectin III-like domains of L1 protein.

---

**Table 3** Mutation detection rate

<table>
<thead>
<tr>
<th>No of age-independent clinical characteristics</th>
<th>No of affected family members</th>
<th>Mutation detection rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;3</td>
<td>1</td>
<td>58 82</td>
</tr>
<tr>
<td>≥3</td>
<td>17 49</td>
<td>18 51</td>
</tr>
<tr>
<td><strong>p≤0.001</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 3** Mutation detection rate

<table>
<thead>
<tr>
<th>No of age-independent clinical characteristics</th>
<th>No of affected family members</th>
<th>Mutation detection rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;3</td>
<td>1</td>
<td>50 91</td>
</tr>
<tr>
<td>≥2</td>
<td>15 68</td>
<td>7 32</td>
</tr>
<tr>
<td><strong>p=0.01</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 3** Mutation detection rate versus number of age-independent clinical characteristics and number of affected family members.
Germline mosaicism of a second male fetus was found to have the same mutation reported.27 40 Du
between the severity of hydrocephalus and the location of those of Kamiguchi
et al,
42%, respectively, found by Michaelis et al,
43% in our group, changes in a key residue led to severe hydrocephalus in 57% of the patients and explained the observation that most of the mutations detected are de novo or a germline mosaicism.
Another striking finding is the very high (~10%) occurrence of de novo mutations in mothers or a germ cell mosaicism in one of the grandparents of index patients. This and the 7% de novo mutations in the index patients means that at least one-fifth of L1 syndrome families have evolved recently, which probably explains the observation that most of the mutations in the L1CAM gene are private mutations.
As a mutation in the L1CAM-encoding DNA sequence was found in 20% of referred cases, the mutation analysis was broadened by analysing 100 patients for potential mutations in the regulatory sequences of the L1CAM gene. This generated no extra mutations, leading to a potential detection rate in these regions of less than 1%. Screening for mutations in the 5’ region was not performed because of this finding and also because too little is known about the function of specific sequences in this region. An MLPA test was used to investigate the same 100 patients for large duplications in the L1CAM gene. Only one duplication, exons 2–10, was detected, suggesting a very low prevalence of this type of mutation. The same seems to be true for large deletions, since, in 73 mutation-carrying patients, only one showed a deletion of the entire gene,19 which is in accordance with previously published results. To date, 169 different L1CAM mutations have been published: 164 small point mutations and five large deletions or duplications including one deletion of the entire gene,13 one deletion of the promoter region and exon 1,17 one deletion of 2 kb at the distal part of the gene c.3545_7
del2kb,41 one deletion of exons 2–5 and part of exon 6,14 and one duplication of 1.5 kb c.3543_7dup1.5kb.42 From these results, it can be concluded that broadening the DNA-screening procedure to include regulatory sequence analysis is not worthwhile. Screening for deletions and duplications may be beneficial, especially in clear clinical cases, although this does not seem to greatly influence the detection rate.

### Table 4 Frequency of the clinical characteristics in a group of patients carrying a mutation compared with a group without a mutation in the L1CAM gene and the positive predictive value

<table>
<thead>
<tr>
<th>Clinical characteristic</th>
<th>Mutation negative</th>
<th>Mutation positive</th>
<th>p Value*</th>
<th>Positive predictive value (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Presence of the clinical characteristic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Hydrocephalus</td>
<td>61</td>
<td>86</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>Aqueduct stenosis</td>
<td>28</td>
<td>68</td>
<td>13</td>
<td>32</td>
</tr>
<tr>
<td>ACC/DCC</td>
<td>14</td>
<td>45</td>
<td>17</td>
<td>55</td>
</tr>
<tr>
<td>Mental retardation</td>
<td>38</td>
<td>73</td>
<td>14</td>
<td>27</td>
</tr>
<tr>
<td>Aphasis</td>
<td>23</td>
<td>58</td>
<td>17</td>
<td>42</td>
</tr>
<tr>
<td>Adducted thumbs</td>
<td>23</td>
<td>37</td>
<td>40</td>
<td>63</td>
</tr>
<tr>
<td>Spatitic paraplegia</td>
<td>20</td>
<td>45</td>
<td>24</td>
<td>55</td>
</tr>
</tbody>
</table>

Patients are taken from the selected group.
*Fisher exact test.
† Significant.
ACC/DCC, agenesis/dysgenesis of the corpus callosum.

Basically, these conclusions relate to the findings of Holden et al,36 who determined the three-dimensional structure of telokin, a protein with a specific domain similar to the L1 Ig domain containing 35 key residues responsible for its structure. The structure of the fibronectin III-like domain and its key residues can likewise be derived from similarities to those of neuroglian.37 Other criteria are whether or not the mutation affects a highly conserved amino acid, is de novo in the index patient, or is only found in affected males and not in unaffected male family members.

Fifteen of the 23 (~65%) disease-causing missense mutations were found to be related to key residues, which is comparable to the findings of Michaelis et al and those of Kamiguchi et al,39 we found no difference in the severity of hydrocephalus in patients with a missense mutation in key residues versus surface residues.35 In our group, changes in a key residue led to severe hydrocephalus in 57% of the patients and surface changes in 50% of the patients, compared with 67% and 42%, respectively, found by Michaelis et al and 78% and 28% determined by Kamiguchi et al, indicating no correlation between the severity of hydrocephalus and the location of the missense mutation in either the key residues or the surface residues.

In five of the 73 patients carrying a mutation (~7%), the mutation was shown to be de novo or a maternal germ cell mosaicism. The latter was confirmed in one case (c.645C→T), as a second male fetus was found to have the same mutation. Germline mosaicism of L1CAM mutations have previously been reported.27 40 Du et al described an unaffected male with a somatic and germline mosaicism of an L1CAM mutation and his two daughters carrying the mutation. The mutation c.645C→T proved to be a special silent mutation that influences the RNA splicing process: a splice donor site arises within exon 6 of the gene. As a consequence, 51 bp or 17 amino acids are deleted. These deleted amino acids are important for the structure of the Ig2 domain and therefore this mutation is considered to be disease-causing.

When no DNA material is available from the index patient, the diagnosis has to be carried out on a close relative, usually the mother. In this study, this was the case in 58 of the 367 patients. In 25 of these 38 mothers, no mutation was detected. Testing the mother has problems because we have shown that 7% of the mutations detected are de novo or a germline mosaicism.

As a mutation in the L1CAM-encoding DNA sequence was found in 20% of referred cases, the mutation analysis was broadened by analysing 100 patients for potential mutations in the regulatory sequences of the L1CAM gene. This generated no extra mutations, leading to a potential detection rate in these regions of less than 1%. Screening for mutations in the 5’ region was not performed because of this finding and also because too little is known about the function of specific sequences in this region. An MLPA test was used to investigate the same 100 patients for large duplications in the L1CAM gene. Only one duplication, exons 2–10, was detected, suggesting a very low prevalence of this type of mutation. The same seems to be true for large deletions, since, in 73 mutation-carrying patients, only one showed a deletion of the entire gene,19 which is in accordance with previously published results. To date, 169 different L1CAM mutations have been published: 164 small point mutations and five large deletions or duplications including one deletion of the entire gene,13 one deletion of the promoter region and exon 1,17 one deletion of 2 kb at the distal part of the gene c.3545_7
del2kb,41 one deletion of exons 2–5 and part of exon 6,14 and one duplication of 1.5 kb c.3543_7dup1.5kb.42 From these results, it can be concluded that broadening the DNA-screening procedure to include regulatory sequence analysis is not worthwhile. Screening for deletions and duplications may be beneficial, especially in clear clinical cases, although this does not seem to greatly influence the detection rate.

### Table 5 Genotype—phenotype correlation

<table>
<thead>
<tr>
<th>Missense mutation</th>
<th>Died before the age of 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>11</td>
</tr>
<tr>
<td>%</td>
<td>92</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Truncating mutation</th>
<th>Died before the age of 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>10</td>
</tr>
<tr>
<td>%</td>
<td>48</td>
</tr>
</tbody>
</table>

*p=0.02 truncating mutation compared with missense mutation.
In contrast with this, the combination of clinical data and the number of affected relatives, obtained via a questionnaire, shows a clear correlation with the mutation detection rate as shown in figure 3. Our findings are therefore of importance for clinicians and genetic counsellors, since they may be used to predict the chance of finding a mutation. Besides, the positive predictive value showing adducted thumbs to be the most predictive may also be quite useful.

Finally, it should be noted that a genotype–phenotype correlation has been identified for the L1CAM gene and its associated syndrome in our group of patients. As previously reported, we also found that children with a truncating gene deletion were more likely to die before the age of 3 than children with a missense mutation. This illustrates that the type of mutation has an important effect on the severity of the L1 syndrome.

CONCLUSIONS

Our study shows that the mutation detection system is efficient for detecting mutations. Using this system, we have clearly shown a correlation between the number of clinical characteristics, the number of affected family members and the chance of finding a mutation. Moreover, we found a genotype–phenotype correlation for L1 syndrome. This study provides a comprehensive tool for genetic counselling.

Acknowledgements

We thank all clinicians for filling out the questionnaires and sending us materials for DNA analysis (notably Gert Matthijs), Annet Vrieling-Kooistra for technical assistance, and Margaret Burton for editing the manuscript.

Competing interests

None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


Genotype–phenotype correlations in L1 syndrome: a guide for genetic counselling and mutation analysis


J Med Genet 2010 47: 169-175 originally published online October 20, 2009
doi: 10.1136/jmg.2009.071688

Updated information and services can be found at:
http://jmg.bmj.com/content/47/3/169.full.html

These include:

Data Supplement
"Web Only Data"
http://jmg.bmj.com/content/suppl/2010/11/16/jmg.2009.071688.DC1.html

References
This article cites 44 articles, 11 of which can be accessed free at:
http://jmg.bmj.com/content/47/3/169.full.html#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Molecular genetics (1044 articles)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/